基础医学与临床 ›› 2008, Vol. 28 ›› Issue (5): 512-515.

• 短篇综述 • 上一篇    下一篇

热休克蛋白70融合肿瘤抗原基因的DNA疫苗研究进展

宗金宝 许雪梅   

  1. 中国医学科学院基础医学研究所 中国协和医科大学基础医学院 中国医学科学院基础医学研究所 中国协和医科大学基础医学院
  • 收稿日期:2001-09-17 修回日期:2007-11-01 出版日期:2008-05-25 发布日期:2008-05-25
  • 通讯作者: 许雪梅

Research progress on the DNA vaccine of HSP70 fused with tumor antigen gene

Jin-bao ZONG, Xue-mei XU   

  1. Institute of Basic Medical Sciences, CAMS & PUMC Institute of Basic Medical Sciences, CAMS & PUMC
  • Received:2001-09-17 Revised:2007-11-01 Online:2008-05-25 Published:2008-05-25
  • Contact: Xue-mei XU

摘要: 在抗肿瘤免疫治疗中,已经发展了多种形式的热休克蛋白70(HSP70)相关治疗性疫苗,这些疫苗主要包括蛋白疫苗、肽疫苗、细胞疫苗及DNA疫苗等,其中HSP70融合DNA疫苗凭借其自身的优势引起人们的关注。它不但可诱导高效、持久的抗肿瘤免疫应答,而且可以维持免疫记忆。本文就HSP70在肿瘤治疗性DNA疫苗中的作用和应用作一综述。

Abstract: A variety of heat shock protein 70(HSP70)-associated therapeutic vaccines have been developed in anti-tumor immunotherapy, including protein vaccine, peptide vaccine, tumor cell vaccine and DNA vaccine, etc, in which HSP70-fused DNA vaccine attracts our attention with its superiority, it not only induces consistent anti-tumor immune response but also helps sustain immune memory. In this article we reviewed the function and application of HSP70 in the therapeutic tumor DNA vaccine.